Allergan’s pipeline doesn’t get enough respect, if you ask Pfizer

Damian Garde Pfizer, wending toward a record-setting $ 160 billion merger with Allergan, said its soon-to-be subsidiary doesn't get the R&D credit it deserves among industry ...

Takeda teams with enGene for gastrointestinal R&D

Damian Garde Japanese drugmaker Takeda signed a deal with enGene to spotlight new therapies for gastrointestinal disease. FierceBiotech News

FDA not satisfied with Cadila’s efforts to fix warfarin production, even after 15 responses

Eric Palmer Cadila Healthcare last week got out in front of bad news by announcing it had received a warning letter from the FDA for two of its Indian plants but was ...

Sanofi drops option, inks $750M R&D collaboration with Warp Drive Bio

John Carroll Three years after Sanofi signed on to back Cambridge, MA-based Warp Drive Bio, taking an option to buy, the pharma giant has stepped back up to retool the terms, opting ...

Pneumonia-stricken Valeant chief takes medical leave of absence

Carly Helfand Last week, Valeant confirmed that CEO J. Michael Pearson had been hospitalized with a severe case of pneumonia–and now, he's taking a medical leave of absence. FiercePharma ...

IPOs: The chill finally set in, so when’s the rally?

John Carroll ​Last year at this time I ended up predicting that we'd see things cool down on the IPO side. Going into the third year of a biotechapalooza of initial public offerings ...

M&A: Buckle your seat belts for another big round of deals

John Carroll With valuations down, buyouts and licensing deals become even more attractive. They're already a requirement. Anyone with a casual acquaintance with the state of Big ...

Valeant’s big pharmacy deal with Walgreens includes quirky drug-buyback plan

Tracy Staton Valeant Pharmaceuticals' much-ballyhooed agreement with Walgreens includes an unusual inventory provision that helps explain why the pharmacy chain might have been ...

FDA approves Lilly and Boehringer’s take on Sanofi’s top-selling insulin

Damian Garde Partners Eli Lilly and Boehringer Ingelheim inched closer to challenging Sanofi's best-selling insulin, winning FDA approval for their take on the blockbuster Lantus ...

AstraZeneca bets on the future of the ‘secretome,’ joining a $100M research effort

Damian Garde AstraZeneca, on the hunt for new drug targets, is teaming up with a Swedish research outfit to explore the potential of an emerging class of proteins, joining a $ 100 ...

CSL, on an expansion sweep, opens operations in Russia

Eric Palmer Australia's CSL has been expanding around the world and now has taken its U.S.-based blood plasma business, CSL Behring, into Russia. It is following other ...

Teva to divest $1B in assets to clear antitrust hurdles to Allergan deal: Reuters

Carly Helfand Back in July, Teva agreed to pick up Allergan's generics business for $ 40.5 billion. To get that deal past regulators, though, it's going to have to divest some ...
Page 2 of 3512345...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS